Keyphrases
Plexiform Neurofibroma
100%
Actionable Strategies
100%
Neurofibromatosis Type 1 (NF-1)
44%
Neurofibromatosis Type I
44%
Drug Combination
22%
Therapeutic Agents
22%
Clinical Trials
11%
Drug Effects
11%
Tumor
11%
Pediatric
11%
High-throughput
11%
Murine Model
11%
Therapeutic Potential
11%
MEK Inhibitor (MEKi)
11%
Additional Treatment
11%
Pre-clinical and Clinical Trials
11%
Drug Screening
11%
Molecular Sequencing
11%
Gene Regulatory Network
11%
Pharmacotherapy
11%
Transcriptome
11%
Inherent Properties
11%
Lifetime Risk
11%
Malignant Transformation
11%
FDA-approved Drugs
11%
Drug Candidates
11%
Network Applications
11%
Screening Data
11%
Network Modules
11%
Biallelic
11%
Macromolecular Drugs
11%
Tumor Predisposition Syndrome
11%
Selumetinib
11%
Benign Nerve Sheath Tumor
11%
Genetic Tumors
11%
Drug Data
11%
Biological Connection
11%
Drug Substructure Fingerprint
11%
Medicine and Dentistry
Plexiform Neurofibroma
100%
Neurofibromatosis Type I
44%
Clinical Trial
22%
Neoplasm
22%
Combination Drug
22%
Neurofibroma Cell Line
22%
Drug Therapy
11%
Disease Predisposition
11%
Pediatrics
11%
Therapeutic Agent
11%
Lifespan
11%
Malignant Transformation
11%
Transcriptome
11%
Drug Screening
11%
Drug Effect
11%
Nerve Sheath Tumor
11%
MEK Inhibitor
11%
Finger Dermatoglyphics
11%
Selumetinib
11%
Diseases
11%
Gene Regulatory Network
11%
Pharmacology, Toxicology and Pharmaceutical Science
Neurofibroma
100%
Neurofibromatosis Type 1
44%
Combination Drug
22%
Neoplasm
22%
Clinical Trial
22%
Pharmacotherapy
11%
Syndrome
11%
Drug Screening
11%
Disease Predisposition
11%
Transcriptome
11%
Malignant Transformation
11%
Mitogen Activated Protein Kinase Kinase Inhibitor
11%
Selumetinib
11%
Nerve Sheath Tumor
11%
Diseases
11%